 | | Vol. 15.44 – 25 November, 2020 |
| |
|
|
| The authors established TRF2 to be largely dispensable for telomere protection in mouse ESCs and epiblast stem cells. ESC telomeres devoid of TRF2 instead activated an attenuated telomeric DNA damage response that lacked accompanying telomere fusions, and propagated for multiple generations.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that TRF2 is dispensable for the proliferation and survival of mouse ESCs. Trf2−/− ESCs did not exhibit telomere fusions and could be expanded indefinitely.
[Nature] |
|
|
|
| Investigators showed that membrane mechanics gate exit from naive pluripotency of mouse ESCs. By measuring membrane tension during early differentiation, they found that naïve stem cells released their plasma membrane from the underlying actin cortex when transitioning to a primed state.
[Cell Stem Cell] |
|
|
|
| Researchers found that shape change was regulated by a β-catenin-mediated decrease in RhoA activity and subsequent decrease in the plasma membrane tension. Preventing a decrease in membrane tension resulted in early differentiation defects in ESCs and gastruloids.
[Cell Stem Cell] |
|
|
|
| Deletion of Strap led to early embryonic lethality and, in embryoid bodies, to abnormal differentiation, indicating an essential role of STRAP in mouse early embryo development and differentiation of ESCs.
[Nature Communications] |
|
|
|
| The authors identified the mechanistic basis for the formation of genome-wide DNA hypomethylation unique to mammals. As the role of TET enzymes in active demethylation is well documented, they investigated their contribution to the hypomethylated state of naïve ESCs.
[Nature Communications] |
|
|
|
| Investigators employed a preclinical model to identify the therapeutic targets of valproate. They used RNA sequencing in both mice and human iPSCs derived from bipolar patients to identify important molecular targets.
[Molecular Psychiatry] |
|
|
|
| iPSCs were generated from family members, and then differentiated to neural stem cells (NSCs). E492K NSCs had reduced neurite outgrowth. A conditional knock-in mouse line, harboring the point mutation in the brain, showed depression-like behavior in the tail suspension test following challenge by physostigmine, a cholinesterase inhibitor.
[Translational Psychiatry] |
|
|
|
| Investigators first defined the transcription factors (TF) reprogramome, i.e., the full complement of TFs to be reprogrammed. Most TFs were resistant to OCT4, SOX2, KLF4, and MYC reprogramming at the initial stages, an observation consistent with the inefficiency and long latency of iPSC reprogramming.
[Scientific Reports] |
|
|
|
| The authors examined the role of Vimentin and its ability to asymmetrically partition aggregates in the process of early differentiation of mouse ESCs.
[Scientific Reports] |
|
|
|
|
| Scientists review the potential mechanism of stem cells as new therapeutic agents in the treatment of diabetic nephropathy (DN). They also review recent findings and updated information about not only the utilization of stem cells on DN in both preclinical and clinical trials but limitations and future expectations of stem cell-based therapy for DN.
[Cell Death & Disease] |
|
|
|
| Human PSCs are a promising alternative to umbilical cord blood- or bone marrow-derived erythrocytes, providing an unlimited source of cells. Human PSCs, including ESCs and iPSCs, are self-renewing progenitors that can be differentiated to lineages of ectoderm, mesoderm, and endoderm.
[Stem Cell Research & Therapy] |
|
|
|
| The authors focus on recent developments of reprogramming somatic cells into iPSCs, neural differentiation towards neuronal progenitors and human sensory neurons.
[Neurobiology of Pain] |
|
|
|
|
| RenovaCare, Inc., developer of patented technologies for spraying self-donated tissue-specific pluripotent cells for the regeneration of skin and other organs and tissues, announced the issuance of two new patents encompassing improvements to the SkinGunâ„¢, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents.
[RenovaCare, Inc.] |
|
|
|
| Caribou Biosciences, Inc. announced the execution of an exclusive license agreement with Memorial Sloan Kettering Cancer Center under which Caribou has rights to fully human anti-CD371 scFvs and intellectual property related thereto in the field of allogeneic CD371-targeted cell therapies including CAR-T, CAR-NK, or iPSC-derived cell products.
[Caribou Biosciences, Inc.] |
|
|
|
|
| June 23 – June 26, 2021
Hamburg, Germany |
|
|
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | The University of Texas Health Science Center at San Antonio – San Antonio, Texas, United States |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Ncardia – Leiden, The Netherlands |
|
|
|
| | Zhejiang University-University of Edinburgh Institute – Haining, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
